OMass Backs MC2 Receptor Strategy With $310 Million to Challenge CAH Standard of Care
OMass Therapeutics has secured $310 million to push OMS1620, its lead small molecule, deeper into development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. The financing gives the Oxford, U.K.-based company the capital to move a mechanism-driven endocrine program into Phase 2 testing, while also supporting earlier pipeline assets.
The size of the raise is a signal of how much commercial and biological attention has shifted toward rare endocrine disease. In CAH, the adrenal glands cannot produce key hormones normally because of an inherited enzyme defect, leaving patients exposed to a cascade of hormonal imbalance, salt wasting, dehydration, and adrenal crisis. Current treatment still leans on high doses of glucocorticoids, which replace missing cortisol but often do so at the cost of broad steroid toxicity. The drug-development challenge has been to find a way to reduce the upstream hormone drive without forcing patients into chronic steroid excess.
OMass is targeting the melanocortin-2, or MC2, receptor in the adrenal gland. Blocking that receptor is meant to blunt the hormonal signaling that drives excess adrenal steroid production in CAH. The company describes OMS1620 as a small molecule designed to stay bound to the receptor longer and retain activity even when hormone levels rise and try to push the adrenal glands harder. In practical terms, prolonged target engagement could matter in a disease where hormonal pressure is relentless and treatment failures often come from biology overpowering a short-lived drug effect.
A Mechanism Built to Reduce Steroid Overexposure
The logic behind OMS1620 is distinct from replacing cortisol with more cortisol. Instead of adding hormone back into the system, the drug aims to reduce the production of the hormones that create the imbalance in the first place. That distinction could prove important in a disorder where the burden of care is not only endocrine instability but also the consequences of long-term glucocorticoid exposure. Excess steroid dosing can bring its own complications, which is one reason the field continues to look for therapies that can normalize adrenal signaling more selectively.
A direct receptor-blocking strategy may also offer a more durable way to reshape the hormonal environment in CAH if the molecule can maintain sufficient occupancy at the adrenal receptor. A receptor-level intervention, by design, sits closer to the disease source than symptom control alone. If the pharmacology holds up in humans, clinicians could potentially see less dependence on high-dose glucocorticoids while still maintaining hormonal balance closer to normal physiology. The company says that is the therapeutic window OMS1620 is intended to occupy.
One sentence captures the clinical ambition: the goal is not merely to treat CAH, but to change how much steroid patients need to survive it.
Competitive Pressure Is Rising Around Rare Endocrine Disease
OMass is not entering an empty field. Crenessity, from Neurocrine Biosciences, is the only FDA-approved treatment for CAH and was approved in 2024. It works differently, blocking CRFR1 to reduce ACTH secretion from the pituitary gland and thereby lower downstream hormone production. Neurocrine reported $301.2 million in Crenessity sales for 2025, a figure that shows both the seriousness of unmet need and the commercial reality OMass will face if OMS1620 reaches the market.
Vertex Pharmaceuticals is also positioning itself in the space through atumelnant, a small molecule ACTH inhibitor that arrived through Vertex’s recent acquisition of Crinetics Pharmaceuticals. The emerging market structure is revealing. Drug developers are converging on separate points in the same endocrine axis: one at the pituitary, another at the adrenal receptor, and potentially others to follow. In CAH, that matters because the disease can be approached from multiple biologic angles, each with different tradeoffs in hormone control, safety, and long-term tolerability.
For patients, more than one effective mechanism could be a good sign. It suggests the disease is finally being treated as a pathway problem rather than a single-drug problem.
Phase 2 Plans Extend Beyond CAH
The new financing is not limited to congenital adrenal hyperplasia. OMass plans to use the capital to advance OMS1620 into Phase 2 testing in both CAH and ACTH-dependent Cushing’s syndrome. That broadens the clinical relevance of the program, since both disorders involve abnormal adrenal hormone signaling, even though the pathophysiology and treatment goals are not identical. The move into a second endocrine indication also reflects the company’s confidence that the receptor biology may have value beyond one rare disease population.
The Series C round, announced Oct. 15, will also support earlier-stage programs. Among them is a potential first-in-class SLC15A4 inhibitor being developed for lupus and other diseases linked to interferon overproduction and pathogenic B-cell activation. For a company built around small molecules, that spread of targets suggests an approach centered on hard-to-drug biology rather than a single asset bet. Still, OMS1620 remains the most visible program because CAH sits at the intersection of rare disease need, chronic steroid burden, and a market already forming around alternative mechanisms.
Investors Are Backing the Endocrine Pipeline Early
The financing was co-led by Bain Capital Life Sciences, Forbion, and Novo Holdings. Janus Henderson Investors, SV Health Investors, Jefferson Life Sciences, Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures, the British Business Bank, and the University of Oxford also participated. The investor mix suggests broad confidence in both the science and the commercial opportunity around endocrine and immunology programs.
Rare disease financing often follows a familiar pattern: capital arrives before certainty, because the biology is hard and the treatment gap is obvious. CAH fits that pattern neatly. Patients face lifelong management, the current standard of care depends heavily on glucocorticoids, and the only approved drug leaves room for competitors that can better balance efficacy with endocrine safety. OMass has now bought itself the time and funding to test whether MC2 receptor blockade can deliver that balance in a way patients and clinicians can actually use.
The next meaningful data will come from Phase 2, where receptor biology meets the reality of human endocrinology.